Дисертації з теми "Protéine kinase CK2 – Inhibiteurs"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 дисертацій для дослідження на тему "Protéine kinase CK2 – Inhibiteurs".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Prudent, Renaud. "Identification et caractérisation d’inhibiteur de la protéine-kinase CK2." Grenoble 1, 2009. http://www.theses.fr/2009GRE10260.
Повний текст джерелаExperimental evidence supports the view that disregulated Protein kinase CK2 is linked to cancers. Elevated CK2 activity in human cancer is an unfavorable prognostic marker. CK2 enhances progression of oncogenesis by regulating various oncogenes, tumor suppressor proteins and protecting anti-apoptotic proteins from caspase-mediated cleavage. Consequently, CK2 has emerged as a therapeutic target and its pharmacological inhibition appears as a promising strategy. Similar to other protein kinases, numerous ATP competitive inhibitors have been identified. However, they display variable effectiveness. Recently, alternative strategies to inhibit this multi-subunit enzyme have been revealed. Screening of chemical libraries using recombinant CK2a could identify compounds that target either the ATP binding site or exosites. These compounds were structurally characterized by analyzing CK2a-inhibitor complexes by means of X-ray structure crystallography or Small-Angle X-ray Scattering (SAXS). These compounds were also evaluated in a novel CK2 cellular activity assay. Several chemically unrelated inhibitors were found to be potent CK2 inhibitor in living cells. Two compounds (ATP-competitive and allosteric, respectively) showed anti-tumor activity, when tested in murine tumor xenograft regression assays. Taken together, this work leads to the identification of the first allosteric inhibitors of CK2, highlighting a new mode of inhibition of CK2. It also demonstrates that targeting an exosite on CK2 is a viable alternative to ATP-competitive inhibitors. This promises new opportunities by exploiting these new mechanisms of action
Lopez, Ramos Miriam. "Conception et synthèse d'inhibiteurs de la protéine kinase CK2." Paris 5, 2008. http://www.theses.fr/2008PA05P633.
Повний текст джерелаThe protein kinase CK2 is engaged in suppression of apoptosis, and its inhibition helps to restore apoptosis. The Library of the Institut Curie was screened, which led to the discovery of new inhibitors. The aim of the thesis work is to improve the inhibition of these molecules to obtain a biochemical tool to investigate the role of this kinase and a potential drug to treat certain forms of cancer. We have synthesized analogues of hit compounds. Molecular modeling allowed a better understanding of how molecules bind in the active site of the protein. We thus obtained a position in the active site of CK2 for each active compound. Co-crystallization of one of the inhibitors helped validating this model. We also performed virtual screening on a subset of compounds from the library
Laudet, Béatrice. "Stratégies pour inhiber une interaction protéine-protéine de haute affinité : l'exemple de la protéine kinase CK2." Grenoble 1, 2007. http://www.theses.fr/2007GRE10172.
Повний текст джерелаMany arguments in favour of oncogenic potential of CK2 protein kinase make it a promising therapeutic target in oncology. This protein kinase is composed of a tetrameric complex of two catalytic subunits CK2a constitutively active and a dimmer of two regulatory subunits CK2b. Our laboratory showed that dynamic interaction between these two subunits in cell is an essential component for this enzyme regulation. For better understanding this regulation in normal and pathologic processes, it seems necessary to develop compounds able to perturb this proteinprotein interaction. In this respect, three complementary strategies were used: 1) hot spots characterization for CK2a-CK2b interaction based on tetramer crystal structure. 2) rational conception of the first antagonist of this interaction as a mimetic cyclic peptide (IC50 = 3 mM). 3) pharmacophore definition based on this peptide allowing to identify chemical molecules analogs by virtual screening. A cluster of chemical compounds active as well in vitro as in vivo has been identified. They represent the first inhibitors for this interaction
Alchab, Faten. "Synthèse et évaluation de dérivés de l'indéno[1,2-b]indole comme inhibiteurs potentiels de la protéine kinase humaine CK2." Thesis, Lyon 1, 2013. http://www.theses.fr/2013LYO10162.
Повний текст джерелаSynthesis and evaluation of indéno[1,2-b]indole derivatives as potential inhibitors of human protein kinase CK2 Protein kinase casein kinase 2 (CK2) is a serine/threonine kinase highly pleiotropic listed substrates it is greater than 500 proteins, which are involved in a wide range of cellular functions. The catalytic subunits of CK2 (α and/or α') are constitutively active either alone or in combination with the regulatory subunits to form a hetero- beta protein holoenzyme). A third isoform of the catalytic subunit, designated CK2 α', was discovered more recently and little information is currently available. The high constitutive activity of CK2 is suspected of contributing to the phenomenal of neoplasia. A design strategy tetracyclic inhibitors targeting the ATP site of CK2 resulted in the development of three series of compounds containing the motif indeno[1,2-b]indole. A multi-step synthesis process has specifically functionalize the D ring of the core indeno[1,2-b]indole and generate a first combinatorial library of original molecules. All final compounds were tested on human protein kinase CK2 (Muenster), and some have reported IC50 of the order of sub-micromolar. Analysis of Structure-Activity Relationships (SAR) and the construction of a 3D-QSAR model (Duesseldorf) helped to refine the choice of substituents introduced into the moleculair frame developed. The indeno[1,2-b]indole the most promising functionalized indoles were also tested on other biological targets such as phosphatase CDC25 A (Metz) and kinase DYRK1B (Saarbruecken). Of molecular modeling studies (Duesseldorf) using the crystallographic data of the enzyme were used to analyze protein-ligand interactions. The most potent in vitro inhibitor were tested on four normal cell lines to determine their cytotoxic profile (Cancer Research Center of Lyon)
Giacosa, Sofia. "Protéine-kinases et cancer du rein : Découverte et validation d’une nouvelle combinaison d’inhibiteurs ciblant les protéine-kinases ATM et CK2." Thesis, Université Grenoble Alpes (ComUE), 2016. http://www.theses.fr/2016GREAV035/document.
Повний текст джерелаRenal cell carcinoma accounts for 3% of all malignant diseases in adults making it the 10th most common cancer in France. The most frequent type of Kidney cancer is Clear Cell Renal Cell Carcinoma (CCRCC). Almost all CCRCC show an inactivation of the Von Hippel Lindau tumour suppressor gene (VHL). Between 25-30% of the patients will develop metastatic renal cell carcinoma (mRCC) by the time they are diagnose or become unresponsive to all treatments and in these cases, the disease has a rapid progression. Over the past years, kinase-targeted therapies (Sunitinib, Sorafenib, Temsirolimus) have become the mainstay of treatment for mRCC, however, most, if not all, patients acquire resistance to these approaches over time.In this context my PhD had 3 goals: a) to find a new combinatory targeted therapy through a High Throughput Screening; b) to establish 3D models mimicking the real environment of the tumours (spheroids, Tissue Slice Culture); c) to validate the Hits through different molecular and cellular biology studies.We conducted a synthetic lethal screen on the CMBA platform (CEA-Grenoble), choosing 36 potential genes targets and 80 kinases inhibitors drugs. Each of the target gene was silenced by a transduction with shRNA Lentivirus into the 786-O cell line derived from ccRCC that lacks the tumour suppressor VHL, is radio- and chemo-therapy resistant, has increased mobility and is highly metastatic. Among the hit combinations that affect cell viability, one of them was chosen because it targets two important kinases involved in cell survival and DNA repair: CK2 and ATM. Moreover, this combination is specifically more active in the 786-O VHL- cells than in 786-O VHL+ cell line. We evaluated the effect of our drugs on the viability of our 786-O VHL+ and VHL- cells in normoxic (21% O2) or hypoxic (1.5% O2) conditions that reflect different environments that are present in a tumour. Surprisingly, in normoxia, we found a synergetic effect of the drug mix only on the 786-O VHL- cells but not on 786-O VHL+ cells. Furthermore, this effect was even stronger in conditions of Hypoxia (up to 20% of synergism).Mechanistically, an up-regulation of the stress pathways was much stronger in the VHL- cells in the presence of the combination than with the drugs alone. No apoptosis was detected in this 2D models. In Multi-Cellular Tumour Spheroid (MCTS) where the organization of a micro-tumour is reproduced, our drugs are even more effective in inducing cell apoptosis than in 2D monolayers of 786-O VHL- cells. These results also demonstrate that pharmaco-modulation of viability of renal tumour organotypic culture by chemical combination targeting protein kinases can be studied. Perspectives of this work are the validation of this drug combination on human renal tumours and the use of organotypic culture as a test for personalized treatment response
Livecchi, Marion. "Synthèse pallado-catalysée de 5-azaindoles et évaluation de leur activité inhibitrice sur les protéines kinases CK2 et Pim-1." Thesis, Paris 5, 2013. http://www.theses.fr/2013PA05P616.
Повний текст джерелаProtein kinases represent promising targets for anti-cancer drug design. In 2003, inhibitors of two of these enzymes, CK2 and Pim-1, were identified by the screening of the Curie Institute/CNRS small-molecule library. The aim of this thesis was to synthesize derivatives of these hits with a 5-azaindole scaffold in order to optimize their biological activity. As the synthesis of such molecules was not reported in the literature, efficient and flexible procedures were developed to access to these structures. Diarylated symmetrical 5-azaindoles were thus prepared by palladium-catalyzed heteroannulation from 4-aminopyridines derivatives. The methodology was subsequently extended to silylalkynes and led to monoarylated products through domino sila-Sonogashira/5-endo cyclization. Finally, a one-pot Sonogashira coupling/aminopalladation/reductive elimination afforded unsymmetrical compounds with a total control of the regioselectivity. Using these methodologies, 70 functionalized molecules were easily prepared. Their cytotoxicity and biological activity as CK2 inhibitors were then evaluated. A structure-activity relationship study was performed, which led to the identification of two key structural elements for the CK2 inhibitory potency of 5-azaindoles
Do, Cong Viet. "Synthèse et évaluation biologique de dérivés hétérocyliques comme agents anti-cancéreux." Thesis, Lyon 1, 2013. http://www.theses.fr/2013LYO10093.
Повний текст джерелаIsocombretastatin A-4 (isoCA-4), a modified combretastatin A-4 (CA-4), was recently discovered known as a strong activity compound to inhibit tubulin polymerization. The vinyl derivatives opened a new series which is hardly exploited. Based on the structure of isoCA-4, we synthesized isoheterocycles series by replacing the B-ring of isoCA-4 by thiophene and benzo[b]thiophene derivatives. These two series were evaluated in their ability to inhibit tubulin assembly. The benzo[b]thiophene derivativesshowed better activity than thiophene derivatives, the binding position 2 of benzo[b]thiophene showed higher activity than position 3. Indenoindoles was known as a potent series to inhibit casein kinase 2 which plays important role in many processes in cell. Based on the structure of indenoindole, we synthesized indenoheterocycles by replacing indole by thiophene and benzo[b]thiophene derivatives. These two series were evaluated in their ability to inhibit CK2. One of the compoundsshowed high activity
Leroy, Didier. "Interaction polyamines/protéine-kinase CK2 : étude moléculaire et fonctionnelle." Grenoble 1, 1996. http://www.theses.fr/1996GRE10046.
Повний текст джерелаLebrin, Franck. "Implication de la protéine kinase CK2 dans la prolifération cellulaire." Université Joseph Fourier (Grenoble), 2000. http://www.theses.fr/2000GRE10164.
Повний текст джерелаMarchin, Stéphane. "Dynamique de la micelle de caséines : caractérisation structurale." Rennes, Agrocampus Ouest, 2007. http://www.theses.fr/2007NSARB180.
Повний текст джерелаCasein micelles play a key rolein milk for its biological and technoligcal functionality. In spite of that, its micellar organization and dynamics are not yet well known. The objective of the thesis was to gain knowledge on the morphology and internal and external structures of native casein micelle, modified by environmental parameters such as pH, temperature and EDTA addition, using a combined biochemical and physical approach. In order to reduce the polydispersity in size and composition inherent to casein micelles, we used different populations of casein micelles varying in size (large, medium and small), separated by differential ultracentrifugation. The combination of small angle and ultra small angle X-ray scattering (SAXS and USAXS) and cryo-transmission electron microscopy (cryo-TEM) has provided fine structural details of the casein micelles. We have shown that colloidal calcium phosphate nanoculsters were present as numerous electron dense areas of about 2. 5 nm. They appeared to be uniformly distributed in a homogeneous tangled web of casein and were primarily responsible for the behaviour of the SAXS intensity curve at the highest q ectors, corresponding to the internal structure of the casein micelles. Secific demineralization of casein micelles by decreasing the pH from 6. 7 to 5. 2 induced a disappearance of the granular characteristic seen in the cryo-TEM images as well as the characteristic point of inflection on the scattering curves
Brachet, Anna. "Organisation du segment initial de l'axone : étude de l'accumulation des canaux sodiques." Aix-Marseille 2, 2009. http://www.theses.fr/2009AIX20736.
Повний текст джерелаGrecu, Dora. "La phosphorylation, par la caséine kinase II, des centrines humaines, régule l'association avec leurs cibles cellulaires." Paris 6, 2013. http://www.theses.fr/2013PA066440.
Повний текст джерелаCentrins are calcium-binding proteins characterized by fours “EF-hand” motifs and by a good conservation among the eukaryotes. The interaction of centrins with several cellular targets has for consequence the association of this protein to various cellular functions, such as involvement in visual phototransduction cascade, DNA repair, centrosome duplication and the export of ARNm from the nucleus to the cytoplasm. The cellular binding partners of centrins are characterized by one or several repetitive the sequence of which is composed of hydrophobic residues in the 1, 4 and 8 position, responsible for the binding to centrins. The function of centrins is regulated by the conformational changes induced by calcium, as well as, by phosphorylation. The thesis work focused on the in vitro casein kinase II protein-phosphorylation process concerning the centrins, and on the study of the effect of the phosphorylation on the binding properties of centrins with their cellular targets, keeping a deep attention to the mechanisms of association to form the complexes. Furthermore, a new cellular target was analyzed during this project: β-Transducin, a protein involved in the visual phototransduction cascade, which is characterized by one centrin-binding motif situated to its C-terminal extremity
Bestgen, Benoit. "Selective modulation of the Protein Kinase CK2 : discovery, syntheses and characterization of non-ATP site inhibitors of CK2." Thesis, Lyon 1, 2015. http://www.theses.fr/2015LYO10247.
Повний текст джерелаThe protein kinase CK2 is a tetrameric enzyme composed of a dimer of regulatory subunits (β) and two catalytic subunits, CK2α and/or CK2α’. The catalytic subunit of CK2 is constitutively active, while the regulatory subunit modulates the selectivity toward a subset of substrate proteins. CK2 is a ubiquitous Ser/Thr protein kinase involved in the control of various signaling pathways, and dysregulation of CK2 promotes cancer development. CK2 has been proved to be a valuable target in cancer treatment. Our objective was to target CK2 outside the ATP-pocket. Two independent classes of compounds were studied: Based on a first hit with a low potency (IC50 = 30 μM) but a non-ATP competitive mechanism of action, several 2-aminothiazole derivatives were synthesized to lead to a potent (IC50 = 0.6 μM) and cell efficient allosteric inhibitor of CK2. Using single mutation scanning, CD spectrometry, STD-NMR and docking experiments, the binding site of our compounds was precisely defined outside the ATP-pocket, at the interface of the glycine-rich loop and the αC-helix. Inhibitors of the α/β interaction were studied from a small cyclic peptide to the development of small molecules through Virtual Ligand Screening. Structures Activity Studies were conducted on the synthesized derivatives and cellular based assays to evaluate the α/β inhibitors were set up. The two classes of compounds developed herein are valuable tools to understand the physiological regulation of the protein kinase CK2, and potential new opportunities in cancer treatment
Das Protein Kinase CK2 ist ein tetrameres Enzym, das aus einem Dimer von regulatorischen Untereinheiten (β) und zwei katalytischen Untereinheiten (CK2α und/oder CK2α’) besteht. Die katalytische Untereinheit der CK2 ist konstitutiv aktiv, während die regulatorische Untereinheit die Auswahl einiger der durch CK2 phosphorylierten Substrate steuert. CK2 ist eine ubiquitäre Proteinkinase, die an der Kontrolle zahlreicher Signalwege beteiligt ist. Eine Fehlregulation der CK2 fördert die Tumorenstehung. Es konnte gezeigt werden, dass CK2 eine vielversprechende Zielstruktur für die Entwicklung neuer Therapeutika ist. Unser Ziel war es, neue Hemmstoffe der Proteinkinase CK2 zu entwickeln, die an anderen Stellen als dem aktiven Zentrum angreifen. Zwei Serien von Verbindungen sind untersucht worden: Basierend auf einem ersten schwach aktiven “Hit” (IC50 = 30 μM), der einen nicht-ATPkompetitiven Wirkmechanismus aufwies, wurden einige neue 2-Aminothiazol-Derivate synthetisiert. Dadurch wurden allosterische Inhibitoren mit einer deutlich gesteigerte Potenz (IC50 = 0,6 μM) und einer beachtlichen Zellaktivität erhalten. Mittels eines CK2- Punktmutanten-Screenings, Zirkulardichroismus-Spektrometrie, STD-NMR und molekularer Docking-Simulationen konnte die Bindestelle unserer Hemmstoffe außerhalb der ATPBindetasche, zwischen der Glycin-reichen Schleife und der αC-Helix, lokalisiert werden. Desweiteren wurden niedermolekulare Inhibitoren der α/β-Interaktion entwickelt, ausgehend von einem zyklischen Peptid sowie von Hitverbindungen aus einem virtuellen Screening. Neue Verbindungen wurden synthetisiert und die Struktur- Wirkungsbeziehungen analysiert; zusätzlich wurde ein Zellassay zur Überprüfung des postulierten Wirkmechanismus etabliert. Die beiden entwickelten Verbindungsklassen sind interessante Werkzeuge, um die physiologische Regulation der Proteinkinase CK2 näher zu analysieren; überdies stellen sie Ausgangspunkte für die Entwicklung neuartiger Krebstherapeutika dar
Vaglio, Philippe. "Etude de la relation structure-fonction de la protéine kinase CK2 par mutagenèse dirigée des résidus basiques conservés." Montpellier 1, 1996. http://www.theses.fr/1996MON1T029.
Повний текст джерелаGouot, Emmanuelle. "Rôle de CK2 dans la dynamique de la chromatine et la précision transcriptionnelle." Doctoral thesis, Université Laval, 2017. http://hdl.handle.net/20.500.11794/28137.
Повний текст джерелаTranscription by RNA polymerase II (RNAPII) is pervasive and aberrant transcripts are permanently generated within cells. Precise and controlled genomic organization in chromatin structure is essential to improve RNAPII accuracy and prevent cryptic transcripts accumulation. Chromatin structure is highly dynamic during transcription, unfolded to give access to DNA and refolded back in the wake of RNAPII to prevent spurious transcription. Multiple mechanisms act together to make this process highly efficient. Casein Kinase 2 (CK2) is a protein kinase ubiquitously present among eukaryotes and implicated in various important cellular processes. Interestingly, a potential function of this kinase in chromatin dynamics through the regulation of chromatin factors has previously been suggested. In this study, we address the role of CK2 in chromatin modulations associated with transcription. We found that CK2 depletion from yeast cells results in an increase of histone turnover in 3’ of transcribed regions and spurious transcription from cryptic promoters. Interestingly, we demonstrate that CK2 modulates directly Spt6 histone chaperone stability and function. This regulation promotes histone recycling during transcription elongation and maintain chromatin organization within coding regions, thereby inhibiting cryptic intragenic and antisense transcription. Our study also suggests that CK2 suppression of spurious transcription extend beyond Spt6 regulation. Indeed, we describe that additional role of CK2 with respect to spurious transcription could be related to its regulation of RNAP II activity through CTD Ser2 phosphorylation. Chromatin regulators such as PAF complex and FACT could also be involved in this regulation process. Finally, we propose that CK2 suppression of spurious transcription is essential for transcriptional optimal and efficient responses to environmental signals. Altogether, our data highlights CK2 signaling pathway as a regulator of transcription accuracy by affecting the essential histone chaperone Spt6, and probably other factors directly involved in the transcriptional process. This mechanism is important to the suppression of cryptic transcription in steady state conditions but also seems to contribute to the fitness of an optimal cellular response to stress signals.
Hamdi, Amel. "Découverte de petites molécules inhibitrices d’interactions protéiques : développements méthodologiques et application à l’interaction CDK2/CKS1." Rennes 1, 2012. http://www.theses.fr/2012REN1S128.
Повний текст джерелаSmall molecule inhibitors of protein interactions are invaluable research tools, enabling a better understanding of regulatory mechanisms. In addition, protein interaction networks represent a relatively untapped, rich source of potential therapeutic targets. Therefore, it is likely that many inhibitors of protein interactions may also represent therapeutic candidates of interest. The discovery of small-molecule inhibitors of protein interactions has been generally considered as an arduous if not impossible task in the past century. However, in the past decade, it has become increasingly popular, partly thanks to the availability of a large arsenal of valuable screening methods. One of the objectives of the PhD work was to optimize a yeast BRET assay (Bioluminescence Resonance Energy Transfer) previously developed in our lab. Although this work has not brought the expected optimization, it has provided a better understanding of the assay in yeast and it has suggested new avenues of optimization. The other objective was to discover small-molecule inhibitors of the interaction between CDK2, a protein kinase that plays a key role in cell division, and the CKS1 regulatory protein. CKS proteins interact with CDK1/2-Cyclin complexes and play multiple roles in regulating the cell cycle and in maintaining mitochondrial genome integrity. Two small-molecule inhibitors of the interaction CDK2/CKS1 were identified by screening a chemical library, using a yeast two-hybrid assay. They have been confirmed by in vitro interaction assays and more active analogues have been identified
Vilmont, Valérie. "Nouvelles voies de régulation des localisations intra- et extra-cellulaires de la protéine FADD." Thesis, Paris 5, 2013. http://www.theses.fr/2013PA05T003.
Повний текст джерелаThe FADD protein (Fas associated death domain) is the key adaptor molecule of the apoptotic signaling pathway triggered by death receptors of the TNF (Tumor necrosis factor) superfamily. During the last decade, it became obvious that, in addition to its major role in cell death, the protein was also involved in other biological processes like the embryonic development, the immune response or even cell cycle progression. Evidence also showed that the protein sub-cellular localization was a key determinant to its functions. Therefore, the identification of underlying regulatory mechanisms dictating FADD expression was of significant importance. In 2008 our laboratory identified, in a thyroid murine model, a new mechanism controlling FADD expression, namely via secretion. We discovered that the loss of FADD expression from tumor cells, by secretion, could be correlated to cancer aggressiveness as well as inflammation (Tourneur 2012). The goal of this thesis work was to apprehend the mechanism by which FADD was secreted and determine, in that case, the modalities of this regulation. A third objective of this work was to identify new potential regulatory pathways of FADD expression. By means of a human cell line model, we showed that, similarly to the mouse model, the expression of human FADD could be regulated via unconventional secretion. In parallel to the characterization of the secretory process itself, we demonstrated that secretion could be negatively regulated by the anti-apoptotic kinase CK2 (casein kinase 2). Finally, we showed that CK2 could regulate FADD nuclear localization via a regulatory sub-unit-dependent phosphorylation and that FADD and CK2 could directly interact. These results are the first to demonstrate that human FADD expression could be regulated via secretion and that FADD sub-cellular localization could be modulated by CK2. The consequences of such regulation with regards to known FADD functions are discussed
Jacq, Jérôme. "Synthèse et propriétés de nouveaux N-hydroxyimides polyaromatiques." Grenoble 1, 2009. http://www.theses.fr/2009GRE10187.
Повний текст джерелаA new route to 1,3-diarylisobenzofurans was developed with the goal to obtain new polyaromatic N-hydroxyimides. It involves the chemoselective addition of aryl magnesium reagents or aryl boronic acids to the aldehyde function of o-aroylbenzaldehydes, themselves obtained by a versatile Kotali reaction. This original method allowed the synthesis of various functionalized 1,3-diarylisobenzofurans and it was applied to the synthesis of 17 new polyaromatic N-hydroxyimides. Diversification reactions without protection of the N hydroxyimide function were successfully performed on these compounds. The biological activity of these compounds was evaluated and allowed the characterization of a new class of Protein Kinase CK2 inhibitors. In addition the synthesized compounds showed a good activity as aerobic oxidation catalysts. All products presented higher activity than NHPI and one of them showed catalytic properties similar to NHTTPI
Gerber-Scokaert, Delphine. "Implication de la protéine kinase CK2 dans la réponse des cellules au stress : une étude des mécanismes de régulation de la localisation de la CK2." Grenoble 1, 2000. http://www.theses.fr/2000GRE10152.
Повний текст джерелаBhat, Abdul Wajid. "Regulation of transcription elongation factors SPT2 and SPT6 by casein kinase II." Thesis, Université Laval, 2013. http://www.theses.ulaval.ca/2013/29184/29184.pdf.
Повний текст джерелаLike any other DNA-related process, chromatin structure is in a state of constant flux during transcription, unfolded to get access to DNA and refolded back properly. The dynamics of chromatin structure are tightly regulated and multiple mechanisms act together to make the process highly efficient. These include modifications of histones, chromatin remodeling by ATP-dependent remodeling factors, incorporation of histone variants and nucleosome disassembly and reassembly by histone chaperones. In addition to these activities, there are a number of non-histone chromatin components that are directly involved in the modulation of chromatin associated with transcription. In yeast, one of these factors is the HMG-like protein Spt2p previously shown to participate directly in the process of nucleosome reassembly in the wake of RNA polymerase II movement along transcribed DNA. In this work, we show that Spt2p is directly phosphorylated by the casein kinase II (CKII) and we demonstrate that this modification inhibits its association with chromatin. Our findings indicate that CKII disrupts the interaction of Spt2p with the histone chaperone Spt6p. Interestingly, we also found that direct phosphorylation of Spt6p by CKII stimulates the association of this factor with another partner, Iws1p. This association is absolutely required for the refolding of nucleosomes during elongation. Furthermore, this positive regulation of the Spt6p/Iws1p complex by CKII modulates directly the association of this complex with the H3K36 methyltransferase Set2p. Finally, we show that phosphorylation of Spt6p by CKII is essential to the inhibition of cryptic promoters and spurious transcription. Taken together, our results suggest a new mechanism whereby CKII directs chromatin structure refolding in coding regions by modulating the interaction of the essential histone chaperone Spt6p with its partners Spt2p, Iws1p and Set2p.
Valero, Emmanuelle. "Mise en évidence, caractérisation, et étude des relations structure-fonction des différentes formes moléculaires de la protéine kinase CK2." Grenoble 1, 1996. http://www.theses.fr/1996GRE10216.
Повний текст джерелаLermet, Anne. "Synthèse d'inhibiteurs de la protéine à activité tyrosine kinase c-kit de type sauvage et muté." Lyon 1, 2006. http://www.theses.fr/2006LYO10026.
Повний текст джерелаBretonnet, Anne-Sophie. "Criblage d'affinité protéine-ligand par RMN et application à la mise au point d'inhibiteurs de la créatine kinase." Lyon 1, 2006. http://n2t.net/ark:/47881/m65b00kb.
Повний текст джерелаThis work details a number of methods used in the design of enzymatic inhibitors, based on Nuclear Magnetic Resonance (NMR). The importance of NMR screening for the study of protein-ligand interactions is described theoretically as well as practically with several real-case applications. These applications include the gathering of a small molecules library, made-up of simple, low molecular weight organic compounds (called fragments) well adapted to affinity screening by NMR methods. The screening of this library for affinity against human serum albumin (HSA) and creatine kinase (CK) is described. Furthermore, molecular modeling and virtual screening are performed on CK to guide the synthesis of novel inhibitors. This example illustrates the importance of structural data in the design of bioactive molecules
Bonnet, Hélène. "Contribution à l'étude de la fonction nucléaire du facteur de croissance FGF-2 : une cible potentielle, la protéine kinase CK2." Toulouse 3, 1996. http://www.theses.fr/1996TOU30142.
Повний текст джерелаBrechet, Aline. "Mécanismes moléculaires de la compartimentation des canaux sodiques au segment initial et aux noeuds de Ranvier : mise en évidence du rôle de la caséine kinase 2." Aix-Marseille 2, 2008. http://www.theses.fr/2008AIX20664.
Повний текст джерелаOuaret, Djamila. "L'enzastaurine, un nouvel inhibiteur sélectif de la protéine kinase Cβ pour le traitement des cancers colorectaux". Paris 6, 2010. http://www.theses.fr/2010PA066734.
Повний текст джерелаMackenbach, Loue Petra. "Translocation nucléaire de la protéine kinase CK2 induite par les facteurs de croissance et surexpression d'une forme anormale de la kinase dans les tumeurs du sein." Université Joseph Fourier (Grenoble ; 1971-2015), 1997. http://www.theses.fr/1997GRE10164.
Повний текст джерелаN'gompaza, Diarra Joannah. "Synthèse et évaluation biologique d’imidazo[1,2-b]pyridazines et de purines inhibitrices de protéines kinases." Thesis, Paris 5, 2012. http://www.theses.fr/2012PA05P613/document.
Повний текст джерелаThis thesis focuses on the synthesis and biological evaluation of new kinase inhibitors. Kinase deregulation is associated with numerous diseases such as cancer or neurodegenerative diseases. In the first part of this work, 2,6,9-trisubstituted purines bearing at C-2 position aminodiols derivatives were prepared. Aminodiols were obtained either via Sharpless asymmetric dihydroxylation or by reduction of amino esters. The compounds appeared to be more potent against kinases than (R)-roscovitine which is presently undergoing phase II clinical tests. In particular, inhibition of CK1, CDK5 and CDK9 were observed with IC50 < 200 nM. The compounds prepared showed an antiproliferative effect against tumor cell-lines (SH-SY5Y). Eventually, one of the most promising compounds was assayed against a series of cyt P450 enzymes and did not showed any inhibition (IC50 > 5 μM). The second family of compounds prepared in this work is imidazo[1,2-b]pyridazines. A new route to 3,6,8-trisubstituted imidazo[1,2-b]pyridazines was first developed. These products were shown to be highly potent inhibitors of several kinases such as CDK5 and CK1 (IC50 < 50 nM). The kinase inhibitions were accompanied by antiproliferative activities against tumor cell-lines. Finally, a series of 3,6-disubtituted imidazo[1,2-b]pyridazines was also prepared and appeared to be selective inhibitors of CLK1 (IC50 < 100 nM)
Hien, Yéri Esther. "Etude des mécanismes d'adressage et de positionnement de l'ankyrine G et de la protéine kinase CK2 au segment initial de l'axone." Thesis, Aix-Marseille, 2014. http://www.theses.fr/2014AIXM5023.
Повний текст джерелаThe axon initial segment (AIS) is responsible for both the maintenance of neuronal polarity and the generation of action potentials. The scaffolding protein ankyrin G (ankG) is specifically expressed in the AIS where it links transmembrane proteins to the subjacent actin and microtubule cytosqueletons. Moreover, the AIS is dynamically regulated by kinases. Although, it has been clearly established that ankG directs AIS assembly and maintenance, the mechanisms regulating ankG proper transport and tethering remain unclear. Another AIS component, the protein kinase CK2 is also playing an important role via the phosphorylation of the ankG-binding motif (ABM) on sodium channels (Nav1) to strengthen their interaction with ankG. But, the mechanism regulating its targeting and anchoring to the AIS remain still unknown. Here, we report that the first 73 residues of the serine-rich domain are necessary for the targeting of ankG to the axon and the tail domain for the proper positioning along the proximal axon. We also observed that ankG axonal localization is modulated by post-translational modifications. Using phosphospecific antibodies and inhibition/depletion approaches, we also provide evidence that the ABM of Nav1 are phosphorylated in vivo and that CK2 accumulation at the AIS depends on Nav1 expression, with which they form tight complexes. This suggests that CK2-mediated phosphorylation participates in Nav1 clustering in vivo and that its specific localization at the AIS is dependent on Nav1 expression. Altogether, our results open new perspectives in understanding the formation of AIS and regulatory mechanisms that may be involved
Esvan, Yannick. "Conception et synthèse de nouveaux composés hétéroaromatiques inhibiteurs potentiels de kinases." Thesis, Clermont-Ferrand 2, 2016. http://www.theses.fr/2016CLF22743.
Повний текст джерелаIn 1950’s protein kinases were found to play a critical role in cell signaling, rising strong research potential for this enzyme family. Initially investigated for their implications in cancerogenesis they were more recently found to be involved in a wide variety of diseases including neurodegenerative pathologies. Herein will be presented two research projects that offer bright new perspectives for the inhibition of kinases involved whether in neurodegenerative diseases or cancers.First, the design and synthesis of new pyrido[3,4-g]quinazoline derivatives will be described as well as their protein kinase inhibitory potencies toward five CMGC family members (CDK5, CK1, GSK3, CLK1 and DYRK1A) that are known to play a potential role in Alzheimer’s disease. The interest for this original tricyclic heteroaromatic scaffold as modulators of CLK1/ DYRK1A activity was validated by nanomolar potencies. CLK1 co-crystal structures with two inhibitors revealed the binding mode of these compounds within the ATP-binding pocket and led to the synthesis of new diversely substituted pyrido[3,4-g]quinazolines.Then the synthesis of a new derivative of the staurosporine aglycon (K252c), in which the lactam ring was replaced by a pyrazole moiety, will be depicted. The resulting indolopyrazolocarbazole inhibited Pim isoforms 1–3 whereas it did not impair the activity of two known targets of K252c, protein kinase C isoforms α and γ . The lead compound exhibited same cytotoxic activity as K252c toward both human leukemia and colon carcinoma cell lines (K562 and HCT116), strongly suggesting that this new scaffold deserves further investigations for treatment of malignancies associated with kinases activities
Laredo, Judith. "Inhibition de la prolifération et chimiosensibilisation des progéniteurs myéloi͏̈des leucémiques et normaux par des inhibiteurs de la protéine kinase C." Toulouse 3, 1994. http://www.theses.fr/1994TOU30134.
Повний текст джерелаZiercher, Léa. "Étude fonctionnelle de la sous-unité régulatrice de la protéine kinase CK2 dans les cellules souches embryonnaires murines : survie cellulaire, oligodendrogenèse et cancérogenèse." Phd thesis, Université Joseph Fourier (Grenoble), 2007. http://tel.archives-ouvertes.fr/tel-00188215.
Повний текст джерелаL'invalidation du gène CK2β chez la souris conduit à un défaut de viabilité des cellules souches embryonnaires (ES). Nous avons pu étudier la fonction de différents domaines fonctionnels in vitro dans un modèle cellulaire reposant sur une stratégie d'invalidation conditionnelle du gène CK2β dans les cellules ES murines. L'abolition de l'expression du gène endogène est létale pour les cellules ES et leur viabilité est restaurée par l'expression exogène de la protéine CK2β sauvage. Ce modèle nous permet d'étudier l'implication de divers domaines de CK2β dans la survie, la prolifération et la différenciation des cellules souches embryonnaires, en remplaçant la protéine endogène par diverses formes mutées de la protéine.
Parallèlement, l'invalidation conditionnelle du gène chez la souris ciblée dans les précurseurs neuraux a montré que CK2β est un élément clef dans les voies de signalisation qui contrôlent l'oligodendrogenèse. La différenciation des cellules ES nullizygotes exprimant la protéine exogène sauvage nous a permis de montrer que celle-ci restaure la lignée oligodendrocytaire. Nous avons aussi montré que certains domaines de CK2β, impliqués dans la fonction régulatrice du dimère, sont des déterminants structuraux cruciaux pour la prolifération des cellules souches neurales et leur progression dans la lignée oligodendrocytaire.
Cinier, Mathieu. "Nouvelles stratégies d'ancrage de protéïnes sur une surface de phosphonate de zirconium." Nantes, 2009. http://www.theses.fr/2009NANT2054.
Повний текст джерелаMiniaturization, automation and high troughput of analysis belong to the current challenges of the genomics and more recently of the proteomics. Progress of nanotechnologies in these fields, in particular with the advent of the biological chips, aim to solve this problem. In this context, we developped two strategies for dense and orientated protein immobilization onto a zirconium phosphonate coated glasss slide:the first one involve synthesis of two bifunctional adaptors. One or two NTA units were conjugated to a multivalent phosphonic acid dipode which interacts strongly with the zirconated monolayer. Zirconated surface fonctionnalized with these linkers have been demonstrated to provide a new selectivity for histagged protein anchoring. The second one involve engineering of a multiphosphorylable tag by Casein Kinase II (CKII) consisting in a nanocluster of four serines. Merged to the C terminal end of an affitin, this tag was demonstrated to be totally and specifically phosphorylated in vitro by CKII. This original phosphate nanocluster based strategy was demonstrated to be effective for selective protein immobilization onto the zirconated support. These both strategies provided uniform orientation of proteins on the chip surface and a higher density of coupling compared to commercial supports. This new technology provides a very high selectivity of anchoring and exhibits high signal to noise ratio compared to other functionalized supports
Deshiere, Alexandre. "Régulation du facteur de transcription SNAIL1 au cours de la Transition Epithélio-Mésenchymateuse dans les cellules mammaires MCF10A : implication de la protéine-kinase CK2." Phd thesis, Université de Grenoble, 2010. http://tel.archives-ouvertes.fr/tel-00568927.
Повний текст джерелаFeizbakhsh, Omid. "La protéine Kinase Haspine comme nouvelle cible thérapeutique : analyse de ses fonctions et caractérisation d'inhibiteurs spécifiques." Thesis, Rennes 1, 2017. http://www.theses.fr/2017REN1B053.
Повний текст джерелаSince its discovery in 1994, Haspin protein kinase has been of growing scientific interest due to its key role in mitosis. It is involved in spatio-temporal localization and activation of Aurora B kinase by creating a specific anchoring site (phosphorylation of Histone H3 on Thr3) on chromosomes and specifically at centromers during early mitosis. Loss of Haspin activity is irremediably accompanied by chromosome alignment errors, centromeric cohesion and mitotic spindle defects. Its essential mitotic functions make it a potential therapeutic target for cancer. The objectives of this thesis were to better understand the functions of Haspin in mitosis, and at the same time, to characterize new specific inhibitors. We have shown that centrosome and mitotic spindle integrity depends on Haspin kinase activity independently of Aurora B activity. In addition, we show that Haspin acts as a negative regulator microtubule nucleation both at centrosomes and on chromosomes. To better understand Haspin's role in microtubule nucleation we looked for new substrates using protein chips. We have identified several candidates including the Nima kinase nucleation effector, Nek9. We confirmed that Nek9 is an in vitro Haspin substrate. In addition, our results showed that Nek9 depletion partly saves the Haspin depletion phenotype, suggesting that Haspin antagonizes Nek9 nucleation function. All of our results demonstrate a new Haspin function in the regulation of microtubule nucleation signaling pathway. At the same time, we have characterized a new series of small inhibitory molecules of Haspin, imidazopyridines derived from CHR-6494. Our hit compounds showed good Haspin inhibitory activity and increased selectivity. Unlike CHR-6494, they have the advantages of not causing cell cycle arrest in G2/M through CDK1 inhibition. They prove to be valuable tools for Haspin function studies and form a strong structural basis for the development of potential therapeutic drugs
Bosc, Nicolas. "Développement de nouvelles approches protéo-chimiométriques appliquées à l'étude des interactions et de la sélectivité des inhibiteurs de kinases." Thesis, Orléans, 2015. http://www.theses.fr/2015ORLE2051/document.
Повний текст джерелаThe human kinome contains 518 proteins. They share a common mechanism of protein phosphorylation known to play an important role in cellular signaling pathways. Impaired kinase function is recognized to be involved in severe diseases like cancer. Due to high structural similarity between protein kinases, development of potent and selective kinase inhibitors is a challenging task. The selectivity of kinase inhibitors may lead to side effects potentially harmful. In this thesis, we first developed new selectivity metrics to determine inhibitor selectivity directly from biological inhibition data. Compared to existing metrics, the new selectivity scores can be applied on diverse inhibition data types. Second, we developed a proteometric approach in order to understand why some protein kinases are never inhibited by Type II inhibitors. The statistical model built for this purpose allowed us to identify several discriminant residues of which few of them correspond to experimentally described residues of interest. Third, using a new 3D protein kinase descriptor, we developed and validated novel proteo-chemometrics approaches to study and discover new kinase inhibitors
Baladi, Tom. "Autour du noyau imidazo[4,5-b]pyridine : inhibiteurs potentiels de la protéine kinase Tyro3 et fonctionnalisation directe de liaisons C – H." Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLS386/document.
Повний текст джерелаBladder cancer is a major medical issue, being the fourth most frequent cancer in men and treatable only with heavy surgery and/or broad-spectrum chemotherapy. This thesis project deals with the discovery of new targeted therapies of bladder cancer by blocking specifically, at a molecular scale in cancer cells, the signaling pathways in which protein kinase Tyro3 is involved. Indeed, its overexpression in most bladder cancers and the major part it plays in cancer cells survival have led to the validation of protein kinase Tyro3 as a therapeutic target for the treatment of bladder cancer. This thesis project can be divided into three main parts: the development of new synthetic methods around the imidazo[4,5-b]pyridine scaffold, the synthesis of a library of compounds using these methods and eventually the study of structure-activity relationships of these compounds versus Tyro3
Kolli, Kaouther. "Rôle de la protéine FAK (Focal Adhésion Kinase) dans les mécanismes d'invasion cellulaire." Thesis, Strasbourg, 2012. http://www.theses.fr/2012STRAJ003.
Повний текст джерелаThis thesis is about the role of the protein FAK (Focal Adhesion Kinase) in the cellular mechanisms of invasion
Rousset, Marine. "Etude des déterminants de l’efficacité et la toxicité des inhibiteurs de kinase utilisés dans le traitement du mélanome métastatique." Thesis, Bordeaux, 2018. http://www.theses.fr/2018BORD0266.
Повний текст джерелаThe combination of BRAF-inhibitors (BRAFi) and MEK-inhibitors (MEKi) has significantly improved the survival of patients with metastatic melanoma with BRAFV600 mutation. About 50% of patients harbour BRAFV600 mutation. BRAFi and MEKi are kinase inhibitors, metabolized by CYP 3A4, responsible for large between-patients variability in plasma concentrations for the same administered dose. About half of patients respond to treatment, and 90% of patients present adverse drug reactions (ADR), requiring dose reduction in 33% of cases. In this context, we described ADR profiles of each of the BRAFi and MEKi in the global pharmacovigilance database, and for ADR that are dose-dependent; we looked for the link between plasma exposure to the drug and the occurrence of ADR. Using the assay method developed, we prospectively measured the plasma concentrations of BRAFi and MEKi in Bordeaux patients, which allowed us to define a toxicity threshold of 48 ng / ml for dabrafenib. This work allowed to deepen the knowledge on the profiles and the occurrence of the ADR for each BRAFi and MEKi. The definition of a toxicity threshold for dabrafenib is a prerequisite for a randomized study to evaluate the value of therapeutic drug monitoring
Lamy, Geneviève. "Etude du rôle des inhibiteurs de kinases-cycline-dépendantes (CKI) de la classe des SIM/SMR en réponse au stress abiotique chez Arabidopsis thaliana." Phd thesis, Université de Strasbourg, 2013. http://tel.archives-ouvertes.fr/tel-00919383.
Повний текст джерелаBendjeddou, Lyamin. "Synthèse et évaluation biologique de nouveaux inhibiteurs de kinases : identification d‘inhibiteurs de kinases parasitaires." Thesis, Paris 5, 2014. http://www.theses.fr/2014PA05P615.
Повний текст джерелаPhosphorylation by protein kinases is one of the most important post-translational modification in cellular processes such as division, differentiation, proliferation and apoptosis. Kinase deregulation is associated with numerous diseases such as cancer or neurodegenerative diseases. Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine were prepared to inhibit protein kinases involved in diseases targeted in the laboratory. The imidazo[1,2-b]pyridazines were synthesized to identify inhibitors of CLK1 and DYRK1A, potential targets in Alzheimer's disease. Among the imidazo[1,2-b]pyridazines synthesized, several molecules were found selective of DYRKs and CLKs, with IC50 < 100 nM. A structure-activity relationship based on the synthesis of 70 molecules, led to the identification of the structural bases of the selectivity. Products were also evaluated against parasite kinases. It was possible to identify some highly potent inhibitors on PfCLK1. The aim of second part of this thesis was to optimize the synthetic process to obtain imidazo[4,5-b]pyridines, which are close analogues of roscovitine. Derivatives had proved capable of inhibiting the formation of cysts in a cellular model of polycystic kidney disease. A seven-step synthesis has led to several grams of 3,5,7-trisubstituted imidazo[4,5-b]pyridine which is now available for evaluation in vivo
Bourayne, Marie de. "Rôle de la CK2 dans l’activation de la réponse immunitaire induite par les molécules allergisantes et son lien avec Nrf2." Thesis, Paris 11, 2015. http://www.theses.fr/2015PA114823/document.
Повний текст джерелаAllergic contact dermatitis represents a severe health problem with increasing worldwide prevalence. It is a T cell-mediated inflammatory skin disease caused by chemicals present in daily or professional environment. Contact sensitizers are low molecular weight compounds termed haptens. These molecules are known to induce an up-regulation of phenotypic markers and cytokine secretion in dendritic cells (DCs), professional antigen-presenting cells, leading to the generation of effector T lymphocytes (LT).We identified a new kinase, termed CK2 (formerly casein kinase 2), as a key kinase in DCs in the acquisition of a mature phenotype and in the production of pro-inflammatory cytokines, involved in T cell polarization in response to contact sensitizers. CK2 activity in DC is necessary to induce a Th1 polarization by controlling the secretion of IFN- by LT, and maintains a pre-existing Th17 response. Moreover, CK2 in DC negatively controls a spontaneous Th2 response.Finally, CK2 controls the expression of Nrf2 target genes mRNA. Nrf2 is a protective transcription factor playing a major role in detoxification, oxidative stress and allergic inflammation generated by contact sensitizers. Nrf2 activation involves different kinases and we highlight that c-Jun could be bound to Nrf2 to generate an active transcriptional complex in response to chemicals
Barkova, Anastasia. "Identification de facteurs cellulaires régulant la rétrotransposition de Ty1 chez S. cerevisiae." Thesis, Université de Paris (2019-....), 2019. https://theses.md.univ-paris-diderot.fr/BARKOVA_Anastasia_2_complete_20190927.pdf.
Повний текст джерелаTransposable elements (TEs) are mobile DNA sequences, with the extraordinary ability to jump and propagate in genomes. Discovered in the 1940s in maize, they are present in all sequenced genomes. Even if a large amount of data reveals their role in evolution, function and structure of genomes, we are still far from understanding every facet of their biological impact on organisms. TEs are not distributed randomly, partly due to mechanisms that target the integration to preferred genomic regions. This is the case for Ty1, a retrotransposon of S. cerevisiae, that targets a one-kilobase window upstream of RNA Polymerase III (Pol III)-transcribed genes. This specificity is due to an interaction between the element-encoded integrase and AC40, a subunit of Pol III. When this interaction is disrupted, Ty1 insertions are redistributed to subtelomeres, which suggests that other factors that regulate the integration selectivity of the retrotransposon exist. The aim of this work was to determine those factors by two complementary approaches. First, we studied the implication in this process of histone variants that correlate with Ty1 integration sites. Second, we identified new partners of Ty1 integrase by a proteomic screen. Our results did not lead us to identifying new cellular factors involved in the recognition of Ty1 integration site. They however widened the array of host proteins that regulate Ty1 retrotransposition. Indeed, we found that the histone variant H2A.Z and the protein kinase CK2 repress Ty1 retrotransposition. CK2 acts at transcriptional and post-transcriptional steps, interacts with the integrase in vivo and phosphorylates it in vitro on several residues in the C-terminal domain, probably thereby regulating its stability. Additional experiments will be required to confirm this hypothesis, to discover by which mechanisms CK2 regulates Ty1, and to understand the role of H2A.Z
Bacevic, Katarina. "Cdk2 as a model for studying evolutionary selection and therapeutic responses in proliferating cancer cells." Thesis, Montpellier, 2016. http://www.theses.fr/2016MONTT184.
Повний текст джерелаCyclin-dependent kinases (Cdk) are essential regulators of the cell cycle that support cell proliferation and are often deregulated in cancer. While Cdk1 is an essential regulator of the cell cycle, Cdk2 is not required for cell cycle progression but promotes tumorigenesis. Therefore, Cdk2 is a promising drug target. Many Cdk inhibitors have been developed and are currently undergoing clinical trials. Darwinian selection can be modelled mathematically, and such studies have shown that even marginal selective advantages can be of great importance in outcomes of cell-cell competition and cancer progression. We hypothesised that the non-essential role of Cdk2 for cell cycle progression may mean that it is a good target for cancer therapy as continual inhibition should be tolerated and should counteract deregulated cell proliferation in cancer. However, as with all chemotherapeutic agents, the development of clinical resistance is likely. We further hypothesized that applying a low-dose treatment with Cdk2 inhibitors should minimize chances of developing resistance, by maintaining competition between robustly proliferating cells that are sensitive to treatment, and resistant cells.The aim of the thesis was to investigate whether Cdk2 confers a proliferative advantage to cancer cells, whether cells can develop resistance to Cdk inhibitors, and if so, whether the mechanisms allowing resistance reduce cellular proliferative fitness.To answer these questions, we have created cell lines with varying degrees of resistance to a selective Cdk2 inhibitor (that at high doses, also inhibits Cdk1) and have characterised their proliferation capacity in comparison with parental cells and isogenic Cdk2 knockout cells. Although in these cells the Cdk2 gene is not mutated and the expression of Cdk2 protein remained unaltered, the kinase activity of Cdk2 is decreased. Similarly, Cdk2 gene knockout (Cdk2 KO) cells have reduced sensitivity to Cdk2 inhibition. Inhibitor-resistant cells proliferate efficiently but are outcompeted by parental, inhibitor-sensitive cells in competition experiments, confirming that inhibitor resistance entails a selective disadvantage. We found that the proliferation of both Cdk2 knockout and inhibitor-resistant (R50) cells is sensitive to nutrient and glucose depletion as well as hypoxia, despite a normal oxygen consumption rate, indicating increased aerobic glycolysis. R50 cells have highly upregulated Cdk6, which may contribute to resistance to Cdk2 inhibition. Moreover, they are sensitised to Cdk4/6 inhibition, which is currently authorised as a treatment for some classes of breast cancer. Finally, Cdk2 knockout cells have an impaired S-phase checkpoint. These results suggest that pharmacological inhibitors targeting Cdk2 might be synthetically lethal with other treatments, eg inhibition of DNA replication, of glycolysis, or of Cdk6. This might diminish cancer cell proliferation and prevent emergence of therapeutic resistance
Miraucourt, Loïs. "Les mécanismes segmentaires de l'allodynie mécanique dynamique : rôle des récepteurs de la glycine dans le système trigéminal." Clermont-Ferrand 1, 2007. http://www.theses.fr/2007CLF1DD07.
Повний текст джерелаThe mechanisms by which simply brushing the skin can evoke pain in pathological conditions still remain unknown. Here, we investigated the mechanisms by which removal of segmental glycine inhibition results in dynamic mechanical allodynia, using behavioral, anatomical and in vivo electrophysiological and pharmacological approaches. We provided a possible mechanism for dynamic mechanical allodynia by showing that a simple switch in trigeminal glycine synaptic inhibition can turn touch into pain by unmasking innocuous input to dorsal horn nociceptive specific neurons through a local excitatory, NMDA-dependent neural circuit involving neurons expressing the gamma isoform of protein kinase C (PKCγ). The process was prevented by pharmacological inhibition of PKCγ, which thus might provide a new treatment of allodynia. We further showed that glycine disinhibition with strychnine selectively induced a morphine resistant, dynamic, but not static, mechanical allodynia which, although relying on the recruitment of superficial lamina nociceptive-specific neurons, did not operate through substance P-receptor activation. We finally found that D-serine, a gliotransmitter that is a co-agonist of NMDA glutamate receptor play a pivotal role in the mechanisms of dynamic mechanical allodynia. In summary, our findings provide a new basic understanding of dynamic mechanical allodynia. They also suggest a new opportunity for a more successful management of this disabling pain symptom
Assrir, Nadine. "Analyse des intéractions moléculaires entre deux protéines liant des histones, HIRA et HIRIP3 (HIRA-interacting protein 3) et leur partenaires respectifs, la protéine chaperon d'histones Asf1 et la sérine-thréonine kinase CK2." Paris 11, 2004. http://www.theses.fr/2004PA11T048.
Повний текст джерелаCardi, Delphine. "Etude du mutant E255L de l'ATPase Ca²+ SERCA1a de lapin et de l'ATPase Ca²+ PfATP6 de Plasmodium falciparum : Expression chez la levure S, cervisiae, purification, characterisation et essai d'inhibition par un antipaludéen puissant, l'artemisinine." Paris 11, 2009. http://www.theses.fr/2009PA11T046.
Повний текст джерелаLebeau, Alexandre. "Conception d’inhibiteurs de l’activité tyrosine kinase basée sur la plasticité conformationnelle : applications aux domaines kinase des protéines Axl, Abl et Src." Thesis, Montpellier 2, 2013. http://www.theses.fr/2013MON20250/document.
Повний текст джерелаThe receptor tyrosine kinase Axl was discovered in 1988. Latter on, its involvement in the cancer development was highlighted. Axl is overexpressed in pancreatic cancer and triple-negative breast cancer cell lines. The success of kinase inhibitors (imatinib, erlotinib ...) led us to focus on the design of inhibitors targetting the kinase domain of Axl. As a guide, we modeled the protein-kinase domain in its active and inactive conformations to perform structure-based drug design. The models were then validated by different methods: structural bioinformatics, comparative docking and focused virtual screening. A virtual chemical library was built and docked into Axl models.Then, I synthetized 15 chemical compounds targetting the ‘inactive' conformation of the kinase domain of Axl. However, none were active in an in vitro assay. Then we were interested in the chemistry of 4 and 7-azaindole cores. This work led to the synthesis of 12 ligands among which several showed promising activity against the ‘inactive' conformation of the kinase domains of Abl and Src.Meanwhile, a large-scale screening was published and we used that new data to re-evaluate the modeling of a "DFG-out" inactive conformation of Axl
Moine, Esperance. "Conception, synthese et évaluation de nouvelles imidazoazines anti-apicomplexes à visée thérapeutique." Thesis, Tours, 2015. http://www.theses.fr/2015TOUR3802.
Повний текст джерелаApicomplexan parasites are ubiquitous and have a strong incidence in veterinary and human medicine. Some of them, like Plasmodium falciparum, causing malaria, or Toxoplasma gondii, causing toxoplasmosis, are matter of public health concern. The existing therapies may have limited efficiency, high toxicity, and may lead to resistance, highlighting the necessity of new more specific approaches. In this context, we have developed two approaches to inhibit Apicomplexa: -the synthesis of biphenylimidazoazines with broad-spectrum and efficient at the micromolar range on five different apicomplexan parasites in vitro. -the synthesis of imidazo[1,2-b]pyridazines specifically targeting a kinase protein (CDPK1) of T. gondii and efficient at the submicromolar range on the parasite in vitro. More than 90% diminution of parasite burden in mice and short term safety make these imidazo[1,2-b]pyridazines good therapeutic candidates
Garnier, Camille. "Rôle de la protéine MAP3K8 et impact de la rigidité dans les cancers ovariens sereux de haut grade." Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCC223/document.
Повний текст джерелаOvarian cancers, which develop in a silent manner in the peritoneal cavity, resulting in a late diagnosis and a poor prognosis, urgently require new therapeutic strategies. In this context, my thesis aimed at better characterize the physical and biological properties of the High Grade Serous ovarian cancers (HGSOCs), accounting for 75% of the tumours.First, we found that the protein MAP3K8 accumulates in HGSOC and is a potential prognostic marker for these tumours. We demonstrated that MAP3K8 controls cancer cell proliferation and migration by regulating key players in Gl/S transition and adhesion dynamics. Importantly, we highlighted that MAP3K8 function is mainly mediated by the MEK pathway, and exhibits a predictive potential for MEK inhibitors, defining them as a promising therapeutic option, in combination with conventional therapy, for HGSOC patients.In a second part of my thesis, we showed that tumor stiffness is increased during tumor growth in HGSOC presenting a "Fibrosis" molecular signature. Moreover, tumor stiffening is associated with high stromal content and remodeling of the collagen network. Interestingly, the MEK kinase was specifically activated upon tumor stiffening. Furthermore, tumor stiffness accompanies a glycolytic metabolic switch, restricted to the central part of stiff tumors. Indeed, the periphery of stiff tumors remains softer than the central part with stromal cells secreting high levels of collagens and showing an OXPHOS metabolism. Thus, tumor stiffness could be at the crossroad of three major processes, i.e. matrix remodeling, MEK activation and stromal metabolic switch, that might explain, at least in part, the progression of HGSOC